After a record year of discovery, biologists race to turn 17,044 new species into medicine

On 14 June 2026, a short wire item from Nikkei Asia carried a number worth dwelling on: 17,044 new species of plants, animals and other organisms were formally described by taxonomists in the year just past — a record. The headline framing was pharmaceutical. Growth in species discoveries, the dispatch said, is fuelling hopes for new drugs. The figure is a triumph of an unglamorous discipline, but it also exposes a fault line running through the economics of biodiversity that no annual tally can resolve on its own. The vast majority of the 17,044 will never be tested for a therapeutic molecule. Whether the few that matter are tested at all depends on access rules, collection permits, and benefit-sharing arrangements that are still being fought over in the same year the discoveries were announced.

The annual cadence of species description is one of the few honest indicators of how much of the natural world humans are still encountering for the first time. It is also, increasingly, a measure of the gap between what is known to exist and what is known to be useful. The 2025 total — a record by every account Nikkei cites — sits at the intersection of two trends that pull in opposite directions. On one side, expeditions into the Indo-Burma and Andean hotspots, the maturation of DNA barcoding, and a long tail of specialist taxonomists working in regional museums are producing more named species per year than at any point in the discipline's history. On the other, the pharmaceutical industry has been steadily pulling back from natural-product screening for two decades, retreating into combinatorial chemistry and, more recently, into computational pipelines that screen vast virtual libraries without ever leaving a server room.

The discovery boom is real, and unevenly distributed

The 17,044 figure is a global aggregate. It is composed of thousands of individual publications in journals from Zootaxa to Phytotaxa, of monographs from natural history museums in Beijing, Berlin, São Paulo and Nairobi, and of revisions of long-neglected insect and fungal groups finally getting the attention that the original 19th-century descriptions never gave them. Nikkei's framing — that the pace of discovery is itself the story — is correct as far as it goes. The same wire item notes that the curve has been climbing almost monotonically for years, and that the share of undescribed species still out there remains large.

What the headline figure does not capture is the geographic distribution of the work. A disproportionate share of the new species are being described from tropical and subtropical countries — precisely the jurisdictions that have spent the last three decades insisting, in venues from Nairobi to Nagoya, that the raw material of their biodiversity should not flow north and west as it did under colonial-era collecting regimes. The Convention on Biological Diversity's Nagoya Protocol, in force since 2014, established a legal floor for access and benefit-sharing (ABS) on genetic resources. The CBD's 2022 Kunming-Montreal Global Biodiversity Framework, agreed at COP15, sharpened that floor by tying biodiversity targets — including the protection of 30 percent of land and sea by 2030 — to financing flows from high-income to low-income countries. Both instruments are now the operating context in which a 2026 drug-discovery expedition is supposed to take place. Whether they are also the constraint is the question that matters.

Why the pharmaceutical industry is not, by default, the customer

The implicit narrative in coverage like Nikkei's is that a growing catalogue of new species enlarges the funnel of candidate molecules, and that the funnel eventually feeds the clinic. The history of the past forty years suggests the funnel is leaking. The share of new molecular entities approved by the US Food and Drug Administration that originate as natural products — or as semi-synthetic derivatives of natural products — fell from roughly 40 percent in the early 1990s to a much smaller single-digit-and-low-teens share in recent years. Screening libraries built from soil microbes, marine invertebrates and tropical plants produced a string of disappointments in the 1990s and 2000s, and the major firms consolidated their natural-product programmes accordingly. The compounds that did reach market — the antibiotics daptomycin and fidaxomicin, the immunosuppressant fingolimod, the anticancer agents trabectedin and eribulin — were developed through narrower partnerships with academic groups and small biotechs rather than through in-house discovery at scale.

That history matters for the 2026 record, because it tells readers what the 17,044 species are not automatically worth. A name, a type specimen, a sequence and a brief morphological description are the inputs to a pipeline, not the pipeline itself. The next steps — collecting sufficient biomass, isolating and culturing the producing organism in many cases, fractionating extracts, screening against disease-relevant assays — are expensive, slow and frequently fail. The default customer for that work is a small set of public-interest research institutes, philanthropic funders and a thin layer of specialist biotechs. The default of the major pharmaceutical firms, with some recent exceptions, is to watch.

The structural frame: who owns a beetle

The deeper question that the annual tally surfaces is one of governance. A species described in 2025 is, in the first instance, a scientific fact. It also becomes — whether its discoverers intend it to or not — a stake in a chain of rights. The Nagoya Protocol and the CBD's access and benefit-sharing rules give source countries a claim on a share of any commercial benefits that flow from use of genetic material from their territory. The Kunming-Montreal framework elevated that claim into a broader political principle: biodiversity is not simply a global commons, it is a stock of value whose returns should be shared. The implementation of that principle, three decades on from Rio, is still uneven. National ABS laws vary widely. Some jurisdictions — Brazil is the most-cited example — have built robust systems of permits and benefit-sharing agreements. Others have not. The resulting uncertainty is itself a deterrent to the sort of long-horizon bioprospecting that produced, for example, the development of the antimalarial artemisinin from Chinese Artemisia annua in the 1970s, in a far more permissive legal environment.

There is a second governance question sitting on top of the first. The new species are described by taxonomists working in institutions that, in most countries, are publicly funded. The type specimens they designate are deposited in museum collections. The data are published in open-access journals under Creative Commons licences. Yet the downstream commercial value, if it ever materialises, is captured privately. The asymmetry is not new. It is the same asymmetry that has long governed academic publishing, open-source software, and the early-stage research that feeds pharmaceutical pipelines. What the biodiversity context adds is an explicit international-law instrument designed to address it. Whether that instrument will do so for the 17,044 species named in 2025 — most of which will generate no commercial value at all, and a small handful of which might generate a great deal — is the part of the story that an annual headline number cannot answer.

Stakes and forward view

The most plausible path forward is not a single breakthrough but a quieter rearrangement. Public-interest consortia — the model used in the antibiotic space, the model used in the open-source malaria drug pipeline of the early 2000s, the model now being attempted in the Cancer Research UK and US National Cancer Institute natural-product programmes — are likely to do more of the early-stage screening of newly described species. Where the molecules are promising, the value of the discovery will in many cases be captured by mid-sized biotechs and academic spinouts rather than by the major pharmaceutical firms. Where the molecules are commercially viable, the supply chain will, under current rules, run back to the source country through an ABS agreement of some kind. The 2030 targets in the Kunming-Montreal framework — and the headline indicator of a record number of new species in 2025 — will both end up in the same set of policy reports. Whether they will end up in the same set of clinical pipelines is a separate question, and one the record number alone does not answer.

What remains genuinely uncertain is whether the 17,044 figure represents the beginning of a discovery acceleration or whether it is a peak that taxonomic capacity will struggle to sustain. The number of working taxonomists has been estimated for years at well below the demand. A long-running funding squeeze in natural history museums in North America and Europe has thinned the institutional base. A new generation of regional institutions in Asia, Africa and South America is rising to fill some of the gap, but the trajectory of the annual total will tell us, in time, which way the balance is moving. The hopeful version of the story is that the 2025 record is a checkpoint, not a ceiling. The honest version is that the record tells us what scientists are naming, not what patients will be taking.

This publication framed the Nikkei Asia wire item as a question about the economics and governance of natural-product drug discovery, not as a celebration of the headline number. The 17,044 figure is a real milestone; what it is a milestone toward is the harder story.

Wire provenance

This editorial synthesis draws on the following public wire/social posts:

• https://t.me/s/NikkeiAsia
• https://t.me/s/NikkeiAsia
• https://t.me/s/nikkeiasia
• https://t.me/s/TSN_ua
• https://www.fda.gov/drugs/development-approval-process-drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products